venBio
View Older Stories View More Recent Stories
-
Form 4 Elevation Oncology, Inc. For: May 25 Filed by: venBio Global Strategic Fund III, L.P.
-
Form SC 13D/A Elevation Oncology, Inc. Filed by: venBio Global Strategic Fund III, L.P.
-
Form 4 Checkmate Pharmaceutical For: May 13 Filed by: venBio Global Strategic Fund II L.P.
-
Form 13F-HR venBio Partners LLC For: Mar 31
-
Form 4 Checkmate Pharmaceutical For: May 05 Filed by: venBio Global Strategic Fund II L.P.
-
Form SC 13G/A Checkmate Pharmaceutical Filed by: venBio Global Strategic Fund II L.P.
-
Form 4 Checkmate Pharmaceutical For: May 02 Filed by: venBio Global Strategic Fund II L.P.
-
Form 4 Checkmate Pharmaceutical For: Apr 27 Filed by: venBio Global Strategic Fund II L.P.
-
Form 4 Checkmate Pharmaceutical For: Apr 22 Filed by: venBio Global Strategic Fund II L.P.
-
Clint Carnell Named CEO of InBrace
-
Orna Therapeutics Bolsters Leadership Team with Key Executive and Board Appointments
-
Form 13F-HR venBio Partners LLC For: Dec 31
-
Form SC 13G/A Metacrine, Inc. Filed by: venBio Global Strategic Fund, L.P.
-
Form SC 13G/A Harmony Biosciences Hold Filed by: venBio Global Strategic Fund II L.P.
-
NorthSea Therapeutics Initiates Phase 1 Trial of SEFA-6179, Targeting the Orphan Indication Intestinal Failure-Associated Liver Disease
-
ImmPACT Bio Closes $111 Million Series B Financing, Names New Board Chair and New President and CEO, and Updates on Phase 1 Clinical Study in Relapsed/Refractory B-cell Non-Hodgkin's Lymphoma
-
Ceptur Therapeutics Launches with $75M Series A Financing to Advance RNA Therapeutics Based on Proprietary U1 Adaptor Technology
-
Form SC 13G CinCor Pharma, Inc. Filed by: venBio Global Strategic Fund III, L.P.
-
Form D OCA venBio IV LLC
-
NorthSea Therapeutics Completes US$80 Million Series C Fundraising to Advance Clinical Programs in Metabolic Disorders
-
Ablaze Pharmaceuticals Launches with $75m Series A Financing to Bring Novel Targeted Radiopharmaceuticals to Treat Cancer Patients in the Greater China Market
-
ACELYRIN, INC. Closes $250 Million Series B Financing and Announces Licensing of Izokibep, a Late-Stage IL-17A Inhibitor to Treat Inflammatory Diseases
-
Icosabutate Latest Phase 2b Interim Data Show Significant Decreases in NASH and Fibrosis Biomarkers Independent of Fibrosis Stage and Disease Severity
-
Form 13F-HR venBio Partners LLC For: Sep 30
-
Form SC 13D Ventyx Biosciences, Inc. Filed by: venBio Global Strategic Fund III, L.P.
-
PPD Reports Third Quarter and Year-To-Date 2021 Results
-
Form 4 Metacrine, Inc. For: Oct 22 Filed by: venBio Global Strategic Fund, L.P.
-
Form 4 Ventyx Biosciences, Inc. For: Oct 25 Filed by: venBio Global Strategic Fund III, L.P.
-
Form 3 Ventyx Biosciences, Inc. For: Oct 20 Filed by: venBio Global Strategic Fund III, L.P.
-
HistoWiz Raises $32M Series A Financing
-
NFlection Therapeutics Appoints William Hodder as CEO and Expands Leadership Team to Accelerate Development of Targeted Treatments for Rare Diseases
-
CinCor Pharma Raises $143 Million in Series B Financing
-
HTG Expands Therapeutics Team
-
Ventyx Biosciences Announces Key Appointments and Closing of $51.0 Million Series B Convertible Preferred Stock Financing Round
-
InBrace Raises $102M Series D Financing
-
Attralus Closes $116 Million Series B Financing
-
Neurogastrx Secures $60 Million in Series B Financing and Expands Management Team to Advance Its Pipeline of Transformative Investigational Therapies for Gastrointestinal Disorders
-
Form 13F-HR venBio Partners LLC For: Jun 30
-
PPD Reports Second Quarter and Year-To-Date 2021 Results
-
Form SC 13D Elevation Oncology, Inc. Filed by: venBio Global Strategic Fund III, L.P.
-
Form 3 Elevation Oncology, Inc. For: Jun 24 Filed by: venBio Global Strategic Fund III, L.P.
-
RayzeBio Secures $108 Million Series C Financing to Drive Forward Its Pipeline of Targeted Radiopharmaceuticals for Cancer
-
venBio Raises $550 Million Venture Capital Fund Focused on Life Sciences
-
Form 13F-HR venBio Partners LLC For: Mar 31
-
Form D venBio Global Strategic
-
Attralus Therapeutics Appoints Mark Timney as CEO and Expands Leadership Team with New Executives
-
Form SC 13D/A Akero Therapeutics, Inc. Filed by: venBio Global Strategic Fund II L.P.
-
Form SC 13G IMPEL NEUROPHARMA INC Filed by: venBio Global Strategic Fund II L.P.
-
Form 4 IMPEL NEUROPHARMA INC For: Apr 27 Filed by: venBio Global Strategic Fund II L.P.
-
Pharvaris Reports Full Year 2020 Financial Results and Provides Business Highlights

